Conduction system pacing (CSP) is being increasingly adopted as a more physiological alternative to right ventricular and biventricular pacing and is an integral part of the European Heart Rhythm Association (EHRA) core curriculum for the device specialist.1–6 Left bundle branch ...
On April 25, 2025, the FDA approved the OmniaSecure defibrillation lead, a 1.6 mm, catheter-delivered, lumenless lead for right ventricular implantation. The small-diameter lead is designed to connect to an implantable defibrillator and treat ventricular tachyarrhythmias, ventricular fibrillation, and bradyarrhythmias, with LEADR trial data showing high implant success, safety, and electrical performance.
Tricuspid regurgitation (TR) is a frequent finding on echocardiography, with detection rates reaching up to 86% across the different ranges of severity, with moderate or greater TR being reported in at least 6–8% of patients.1–3 The prevalence of TR increases with age, ...
The first-in-human implantation of a leadless pacing system occurred already more than 10 years ago.1Â The first-generation ventricular leadless pacemaker could provide only asynchronous ventricular pacing (ventricular, ventricular, inhibited [VVI], or ventricular, ventricular, inhibited, rate response [VVIR]), limiting its indications to ...
In this interview, Dr. Margarida Pujol-Lopez from the Hospital Clinic in Barcelona discusses the differences between conduction system pacing (CSP) and biventricular pacing (BVP) in treating heart failure. CSP is more physiological and may offer better outcomes than BVP, which fails in about 30% of patients. The CONSYST-CRT trial, comparing CSP and BVP, showed that CSP is non-inferior to BVP based on primary and secondary endpoints, including mortality, heart failure, and QRS shortening.
Catheter ablation (CA) is an invasive adjunctive therapeutic option for atrial and ventricular arrhythmias, in uncontrolled cases, following optimal medical therapy.1,2Â The validation of 3D mapping and its implementation into clinical usage has been a remarkable achievement in the field ...
For decades, right ventricular pacing (RVP) has been the leading pacing technique and has been proven to be effective in treating patients with symptomatic bradycardia. However, dyssynchrony caused by non-physiological ventricular activation results in pacing-induced cardiomyopathy occurs in approximately 15% of ...
Highlights Failure to target and deliver durable radiofrequency lesions to all functionally critical areas has been identified as an important cause of ventricular tachycardia recurrence and is particularly challenging in deep midmyocardial or very extensive substrate where point-by-point radiofrequency ablation ...
Bradycardia, renal failure, atrioventricular nodal blockade, shock and hyperkalemia (BRASH) syndrome is a rare, often unrecognized but potentially life-threatening clinical entity that is characterized by the pentad of symptoms after which it is named. BRASH syndrome is seen most commonly ...
The AdaptResponse trial was designed to assess two methods of restoring resynchronization to the heart in patients with heart failure with left bundle branch block. In this touchCARDIO interview, we speak with Dr Bruce Wilkoff (Cleveland Clinic, Cleveland, OH, USA) ...
Tricuspid regurgitation (TR) is a complex disease with several independent causes. Consequently, outcomes and response to therapy vary widely. Severe or progressive TR often results in gradual right ventricular (RV) failure and is associated with poor long-term outcomes.1Â Most cases ...
Conventionally, according to the European Society of Cardiology pacing and cardiac resynchronization therapy (CRT) guidelines, patients with clinical heart failure and an echocardiographically measured left ventricular (LV) ejection fraction of <35% are considered for CRT implantation or standard right ventricular (...
Lead displacement in pacemakers is a common implantation-related procedural complication, often resulting in prolonged hospital stays for patients and increased healthcare costs.1,2Â The frequency of long-term lead displacement ranges between 1.8% and 8.0%.3,4Â Recognizing lead displacement complications is an essential part of ...
Vasovagal syncope is common, and while it is usually associated with a benign prognosis, it results in significant physical and psychological morbidity for affected individuals. Despite comprehensive understanding of the underlying pathophysiology, there have been few definitive therapeutic advances until ...
Atrial fibrillation (AF) and heart failure (HF) often co-exist. The incidence of AF is estimated to reach 45% of patients with HF and rises with the severity of HF symptoms, from about 5% of patients in the New York Heart Association (NYHA) ...
The current outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has developed into a worldwide pandemic affecting millions of lives in one way or another.1 Over the period of 1 year since the disease was first ...
Several closely regulated ion channels are involved in the various phases of the myocardial action potential (phases 0–4) (Figure 1).1 In the absence of neuroendocrine and other regulatory signals, the pacing rate of the sinoatrial node is 100 beats per minute (bpm). However, ...
Supraventricular tachycardia (SVT) occurs with a prevalence of 2–3/1,000 in the general population and is characterised by atrial rates >100 beats per minute (bpm) at rest. Per definition, SVT originates in the atria or atrioventricular (AV) node tissue above the His ...
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.